Veravas names Michael Willoughby Chief Executive Officer

AUSTIN, TX, UNITED STATES, October 19, 2026 /EINPresswire.com/ — Veravas Names Michael Willoughby Chief Executive Officer

FOR IMMEDIATE RELEASE
Aaron Chalekian named Chairman; cofounder John Forrest to remain on the Board of Directors
AUSTIN, Texas – October 19, 2026 – Veravas, Inc., an Austin-based clinical diagnostics company focused on early detection and prognostic screening for Alzheimer’s disease and other neurological conditions, today announced the appointment of Michael Willoughby as Chief Executive Officer, effective today. He succeeds cofounder John Forrest, who will remain on the Board of Directors.
Board member Aaron Chalekian has been named Chairman.
Willoughby is a healthcare executive and entrepreneur with more than 25 years of experience building and scaling diagnostics, genomics and healthcare services businesses, from early-stage development through commercialization and a successful exit. He founded GX Sciences, a molecular diagnostics laboratory that he scaled and sold to Fagron Genomics US, and previously served as Vice President of Remote Operations at Clinical Pathology Laboratories, leading its Southwest division, a business with approximately $300 million in annual revenue and more than 1,500 employees. He works closely with key opinion leaders in neurology and personalized medicine, including physicians specializing in Alzheimer’s disease.
“On behalf of the Board, I want to thank John for his leadership and contributions as the cofounder of Veravas. We are pleased that he will continue to serve on the Board,” said Chalekian, a Veravas Board member since 2025 and a Vice President of R&D at Boston Scientific. “Michael brings the diagnostics industry experience, commercial focus and operational leadership to guide Veravas through its next stage of growth.”
“Veravas has an important opportunity to address the need for earlier, more informative diagnostics for Alzheimer’s disease,” said Willoughby. “My focus will be on translating the team’s scientific progress into commercial execution, building strong clinical relationships and preparing the business to scale.”

About Veravas
Veravas is a leading innovator in clinical diagnostics focused on early detection and prognostic screening for Alzheimer’s disease and other neurological conditions. The company’s proprietary VeraBIND™ technology transforms challenging sample types into measurable biomarkers, enabling earlier disease detection and the development of novel diagnostic tests. Its VeraBIND Tau assay is a first-in-class blood-based test that measures the pathological activity of hyperphosphorylated tau in blood samples of cognitively normal individuals or individuals experiencing cognitive impairment which may be used to aid in the diagnosis of Alzheimer’s disease. Learn more at Veravas.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including statements about the leadership transition, the company’s strategy and its anticipated milestones. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Veravas undertakes no obligation to update any forward-looking statement, except as required by law.
Contact
Michael Willoughby
Chief Executive Officer
Michael@veravas.com
1.512.688.6938

Luc.Vanhal
www.VERAVAS.com
+1 310-418-1666

Media gallery